Lenacapavir: an attractive option, but proceed with caution
- PMID: 37451298
- DOI: 10.1016/S2352-3018(23)00170-4
Lenacapavir: an attractive option, but proceed with caution
Conflict of interest statement
MH has received consulting or advisory fees and honoraria administered by her institution from Gilead Sciences Canada, Merck Canada, and ViiV Healthcare.
Comment on
-
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11. Lancet HIV. 2023. PMID: 37451297 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical